Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy

Next Previous
Trial Profile

Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anagrelide (Primary) ; Busulfan (Primary) ; Interferon (Primary) ; Ruxolitinib (Primary) ; Hydroxycarbamide
  • Indications Myelofibrosis; Thrombocytopenia
  • Focus Therapeutic Use
  • Acronyms MOST
  • Sponsors Incyte Corporation

Most Recent Events

  • 03 Jun 2025 According to an Incyte corporation media release, data from the study will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 -15, 2025, in Milan.
  • 25 Nov 2024 According to an Incyte Corporation media release, data from this study will be presented t the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego
  • 14 May 2024 According to Incyte media release, data from this trial will be presented at the European Hematology Association 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top